ClinicalTrials.gg
Active, not recruitingNCT07285278Updated May 11, 2026

Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

A Phase 2 interventional study of ABO1108 and Placebo in Varicella-zoster Virus, sponsored by Suzhou Abogen Biosciences Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Suzhou Abogen Biosciences Co., Ltd. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Chickenpox with a site in China — 7 open to participants now, 12 under way, 4 of them phase 3. Chickenpox · China.

Planned enrollment
28th of 31
300 · median 899
Started
2025
with 4 others
Phase 2
2 of 31
none open now
Primary completion
2026-03
later than 9 of 11 live
Registered
28th of 31
by date
Lead sponsor
3 of 31
Suzhou Abogen Biosciences Co., Ltd.

Among the 31 studies in Chickenpox with a site in China, this one is the 28th largest by planned enrollment, is one of 5 that started in 2025, is one of 2 in phase 2, reaches primary completion later than 9 of the 11 other live ones, and was the 28th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

7 of the 31 studies in Chickenpox with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Chickenpox with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.

03

Conditions studied

  • Varicella-zoster Virus

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the Form (ICF) approved by the Ethics Committee and agree to participate in the trial before undergoing any trial procedures.
  2. Healthy adults ≥40 years of age, participants with underlying diseases that are stably controlled may be accepted.
  3. Willing to and physically able to communicate with the investigators, understand and comply with protocol required follow-up, simple self-observation and recording using the Diary Card.
  4. Male participants (and their female partners) and female participants of agree to continue effective through 6 months following vaccination.

Exclusion criteria

Exclusion Criteria:

  1. Acute illness or fever on the day of vaccination or within 3 days prior to vaccination, or use of anti-inflammatory, anti-allergy, antibiotic, or antiviral medications due to physical discomfort.
  2. abnormal vital signs, including but not limited to:

    • Resting pulse rate \<50 beats per minute or >100 beats per minute, participants with resting pulse between 100 to 110 without significant symptoms, such as palpitations, chest tightness, dizziness and fatigue, will be accepted.
    • Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg for participants aged 40-59, or systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg for participants aged ≥60
    • (BMI) ≥30 kg/m²
  3. Female participants known to be pregnant or breastfeeding, or positive pregnancy test for women of .
  4. History of allergy to any ingredient of the products, or severe allergic reactions to other vaccines, foods, or medications.
  5. History of herpes zoster at any previous time, history of varicella or close contact with varicella/herpes zoster patients within the past year.
  6. Previous vaccination with herpes zoster or varicella vaccine (including marketed or investigational vaccines) or planned vaccination during the trial period.
  7. Use or planned use of any vaccine other than the investigational products through 30 days prior to and 30 days after vaccinations in this trial.
  8. Current participation in another clinical trial within 6 months prior to vaccination or planned participation before the end of this trial.
  9. Clinician-diagnosed coagulation abnormalities.
  10. Known medical history or diagnosis confirming the subject has a condition affecting immune system function.
  11. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or presence of any condition that may increase the risk of myocarditis or pericarditis.
  12. Severe or uncontrolled respiratory, cardiovascular, neurological, hematological, lymphatic, hepatic, renal, metabolic, or skeletal diseases; known severe congenital malformations; developmental disorders; or clinically diagnosed severe chronic conditions that may affect trial outcomes.
  13. Current infectious period of any communicable disease, acute infection, or acute phase of chronic infection, or ongoing anti-tuberculosis treatment; or prior positive test for surface antigen, virus antibody, or Treponema pallidum antibody.
  14. Past or current diagnosis of neurological or psychiatric disorders, or family history of neurological/psychiatric disorders; or other neurological conditions deemed unsuitable for trial participation by the investigator.
  15. Long-term use of or immunomodulators through 6 months prior to and one month after the last vaccination, excluding topical medications. Topical medications should not exceed recommended doses or induce systemic exposure.
  16. Treatment with immunoglobulins and/or blood products or blood donation through 3 months prior to and one month after the last vaccination in this trial.
  17. Suspected or known alcohol dependence or drug abuse, which may affect safety assessment or trial compliance.
  18. Planned long-term or permanent relocation away from the trial site area before trial completion.
  19. Investigators, sponsors, and contract research organization (CRO) staff directly involved in the trial.
  20. Other circumstances deemed unsuitable for trial participation by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Group 1: Dose level A in adults aged 40 years or above

    Two injections of Dose level A of ABO1108 given approximately 60 days apart

    Biological: ABO1108

  • Experimental
    Group 2: Dose level B in adults aged 40 years or above

    Two injections of Dose level B of ABO1108 given approximately 60 days apart

    Biological: ABO1108

  • Placebo comparator
    Group 3: Placebo control in adults aged 40 years or above

    Two injections of placebo given approximately 60 days apart

    Drug: Placebo

Interventions

  • BiologicalABO1108

    Formulation for injection

  • DrugPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean value (GMT or GMC) of Serum gE-specific IgG antibody and VZV antibody

    Time frame: Up to Day 90 (30 days after the last dose)

  2. Geometric Mean Increase versus Postbaseline/Baseline Ab Titers

    Time frame: Up to Day 90 (30 days after the last dose)

  3. gE-specific T cell responses

    Time frame: Up to Day 90 (30 days after the last dose)

07

Study locations

1 site
  • Rongshui Miao Autonomous County Center for Disease Control and Prevention
    Liuzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Mar 2026, 3 months.

Of 17 phase 2 interventional studies under Chickenpox, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 16, 2025
StartActual
Nov 15, 2025
Primary completionActual
Mar 9, 2026
CompletionEst.
Feb 15, 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07285278
Lead sponsor
Suzhou Abogen Biosciences Co., Ltd.
Collaborators
Abogen Biosciences (Shanghai) Co., Ltd
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Nov 15, 2025
Primary completion
Mar 9, 2026
Completion
Feb 15, 2027 (estimated)
Last update
May 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABO1108

Start the discussion